Short Interest in Moleculin Biotech, Inc. (NASDAQ:MBRX) Decreases By 42.7%

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the recipient of a significant decline in short interest in March. As of March 13th, there was short interest totaling 109,555 shares, a decline of 42.7% from the February 26th total of 191,156 shares. Based on an average daily volume of 152,358 shares, the short-interest ratio is currently 0.7 days. Approximately 5.4% of the company’s stock are short sold.

Institutional Investors Weigh In On Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC bought a new position in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned 1.11% of Moleculin Biotech at the end of the most recent quarter. Institutional investors own 15.52% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Roth Mkm reiterated a “buy” rating on shares of Moleculin Biotech in a research report on Monday, December 15th. HC Wainwright reissued a “buy” rating and set a $22.00 target price on shares of Moleculin Biotech in a research report on Tuesday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $22.00.

Moleculin Biotech Trading Up 0.4%

MBRX traded up $0.01 during midday trading on Friday, reaching $2.44. The company’s stock had a trading volume of 82,210 shares, compared to its average volume of 174,715. The stock has a market cap of $4.98 million, a P/E ratio of -0.07 and a beta of 1.73. The company has a fifty day simple moving average of $3.26 and a 200 day simple moving average of $6.88. Moleculin Biotech has a twelve month low of $1.79 and a twelve month high of $28.61.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.